Commercial launch readiness is a critical stage in a product life cycle. While the world hangs on pharma’s ability to discover a COVID cure or vaccine, the global economic downturn will only increase price pressures overall for the industry. The era of increasing competitive and price pressure is not going away and capturing full value from every product launch is critical. However, history shows that only a third of product launches meet analyst expectations. Teams with the ability to optimize commercial launch readiness through insight, differentiation, efficiency, and risk mitigation will lead the pack.
Often teams, whether in a start-up, mid, or large pharma, lack extensive experience in commercial launch readiness. This influences the brand’s ability to meet forecast and achieve market access targets. Leveraging the breadth and depth of launch experience from dozens of launches across primary care, rare disease, oncology and specialty, this webinar will discuss typical commercial launch readiness risk areas, best practices approaches for commercial readiness and securing market access, and measurement.
Beth Schurman, Partner, Herspiegel Consulting
Beth Schurman has helped to grow Herspiegel Consulting during the last 12 years into a world-class firm helping clients with commercial strategy, innovation and execution. She has been involved in new product commercialization and brand optimization across oncology, CNS, metabolic disease, dermatology, women’s and men’s’ health from rare disease to blockbuster brands. Prior to Herspiegel Consulting, Schurman worked on the client side in marketing roles at Bristol-Myers Squibb and Novo Nordisk.Message Presenter
David Rees, Market Access Practice Lead, Herspiegel Consulting
David’s Rees market access expertise is built on 25+ years of experience assisting clients in developing strategies to optimize brand access in the competitive biopharmaceutical market. Rees’s creativity, strategic acumen, deep market insight, and client focus have earned him an industry-wide reputation among market access professionals. Prior to joining Herspiegel Consulting, Rees co-founded Health Strategies Group and was instrumental in building its industry-leading reputation for strategic insight in the rapidly evolving US access landscape.Message Presenter
Who Should Attend?
Director and Senior Level professionals from biopharmaceutical companies working within: Pharmaceutical and Biotech Commercial Organizations including leaders of marketing, market access, medical affairs and commercial operations teams, omnichannel, market shaping leaders. Director, VP and C-Suite level executives.
What You Will Learn
In this webinar, speakers will present:
- Insights from pharmaceutical and biotech product commercial launch readiness including commercialization trends, typical launch readiness challenge areas, and management approaches resulting in forecast attainment.
- Case examples from a co-promoted oncology product, a category creating launch executed during COVID lockdown, and others.
Herspiegel Consulting specializes in pharmaceutical and biotech commercialization helping clients with strategy through execution in five core service areas of new product planning, marketing, launch readiness, medical affairs, and market access. Herspiegel Consulting offers integrative, tailored consulting services to meet your brand and business needs. Our diverse team brings experience from over 65 product launches, strategy and innovation leadership, and executional support for start-up to large pharma clients. We have experience across a wide variety of therapeutic areas including oncology, rare disease, metabolic disease, CNS, women’s health, and others.